(Total Views: 456)
Posted On: 08/20/2021 2:53:24 PM
Post# of 154977
The FDA will not be giving any free passes like they did to Aduhelm, at least while they're still under scrutiny. Now they just need to receive some scrutiny for hindering drugs with a p=.0032 value.
As far as Sesen goes there's a reason why they should have gotten a CRL. They were already having problems with the BLA when I got out in 2019.
As far as Sesen goes there's a reason why they should have gotten a CRL. They were already having problems with the BLA when I got out in 2019.
Quote:
Sesen Bio shares crater after report of trial misconduct for bladder cancer drug
https://www.fiercebiotech.com/biotech/sesen-b...ancer-drug
(3)
(0)
